Precision Medicine
7 min read
September 28, 2026
Doctor Reviewed
Targeted Molecular Inhibitors: EGFR, ALK & Next-Gen TKIs Explained
Understanding how oral tyrosine kinase inhibitors like Gefitinib (Geftinat) and Erlotinib selectively block cancer cell signaling pathways with fewer systemic side effects than IV chemotherapy.